Last reviewed · How we verify

NCT05367882

Effect of Interleukin 6 Receptor Antagonists in SARS-CoV-2 Patients

Completed Last updated 25 July 2023
What this trial tests

trial testing ELISA in Corona Virus Infection in 96 participants. Completed in 24 July 2023.

Timeline
1 February 2022
Primary endpoint
20 July 2023
24 July 2023

Quick facts

Lead sponsorAssiut University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment96
Start date1 February 2022
Primary completion20 July 2023
Estimated completion24 July 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Investigate the possible effects of interleukin-6 receptor antagonists such as tocilizumab and sarilumab on the levels of IL-6, inflammtory and anti-inflammtory markers and cytokines before and after treatment in critically ill corona virus disease-19 patients. 2. Correlate between IL-6 levels with other inflammatory markers as ferritin and C-reactive protein. 3. investigate the possible changes on the levels of other inflammatory, anti-inflammatory markers and cytokines such as IL-10 and IP-10, before and after treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ELISA

Trials testing the same drug.

Other recruiting trials for Corona Virus Infection

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing